Cerebral venous thrombosis (CVT) is rare and accounts for 0.5% of all strokes. Its clinical
presentation is variable and diagnosis requires a high index of clinical suspicion in conjunction …

Background Antiplatelet therapy reduces the risk of major vascular events for people with
occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. …

Cerebral venous thrombosis (CVT) is a condition that can affect all age groups and can
often be difficult to diagnose and treat. The difficulties in diagnosis are mainly due to the non-…

Background There is an increased attention to stroke following SARS-CoV-2. The goal of
this study was to better depict the short-term risk of stroke and its associated factors among …

Background and Purpose: Stroke is reported as a consequence of severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) infection in several reports. However, data are …

Importance The Restart or Stop Antithrombotics Randomized Trial (RESTART) found that
antiplatelet therapy appeared to be safe up to 5 years after intracerebral hemorrhage (ICH) that …

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might
reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with …

Objective To identify characteristics, predictors, and outcomes of acute symptomatic seizures
(ASS) in cerebral venous thrombosis (CVT), we investigated 1,281 consecutive adult …

Background and Purpose— Transcranial Doppler ultrasound can reliably detect both gaseous
and solid cerebral emboli. However, conventional equipment is unable to discriminate …

Background and purpose To explore the prevalence, risk factors, time correlation,
characteristics and clinical outcome of dural arteriovenous fistulas (dAVFs) in a cerebral venous …